All News
Comorbidities Increase in Importance in RA
Patients with rheumatoid arthritis (RA) have a large comorbidity burden at the time of diagnosis, including a wide range of ailments but with pulmonary disease a particular concern, a U.K. population-based study found.
Read Article
Joint Injections: Are They Worth the Risk?
Intra-articular injections of corticosteroids for relief of the pain of hip or knee osteoarthritis (OA) may have adverse long-term consequences, researchers suggested.
Read Article
Protective Effects of ASA and Vasodilators in Systemic Sclerosis
A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable cardiovascular outcomes.
Read Article
Stress and the Risk of Incident Inflammatory Arthritis
A prospective analysis of newly diagnosed, inflammatory arthritis (IA) patients suggests that perceived distress (stress) increases the odds of incident IA.
Read Article
Hydroxychloroquine Blood Levels May Predict Future Retinopathy
A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.
Read Article
Juvenile Arthritis at Risk for Coronary Artery Disease
Arthritis Care & Research reports that juvenile arthritis (JA) patients may have a higher risk if coronary artery disease (CAD) in adulthood.
Read Article
RheumNow Podcast – When You’re Hot You’re Hot (10.11.19)
Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.
Read Article
Long Delays for Inflammatory Arthritis Patients
The National Rheumatoid Arthritis Society's (NRAS) annual audit has identified significant treatment delays for patients with suspected early inflammatory arthritis could result in unnecessary harm.
Read Article
Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis
Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?
Read Article
Antibiotics Increase Rheumatoid Risk - Again
Another UK study has suggested that prior use of antibiotics increases the risk of developing rheumatoid arthritis (RA).
Read Article
RheumNow Podcast – Women Take Over Rheumatology (10.4.19)
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
Read Article
Anakinra Use in Hospitalized Gout Patients
While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.
Read Article
RheumNow Podcast – Cancer Risk in Systemic Sclerosis (9.27.19)
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
Read Article
Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors
Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.
RheumNow Podcast – The End of Arthritis (9.13.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis
A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.
Read Article
Bimekizumab Add-on Therapy in Rheumatoid Arthritis
Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.
Read Article
74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment
CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).
Read Article
RheumNow Podcast is up! When youre hot youre hot! Watch it on youtube>> https://t.co/GlqMzjUnhE or listen to the podcast in your car on iTues, Apple podcast or on Stitcher or SoundCloud>> https://t.co/a1zE7VXtog
Links:
Dr. John Cush RheumNow ( View Tweet)
Nucala (mepolizumab) was approved in 2015 for severe eosinophilic asthma, and in 2017 for EGPA (Churg Strauss). The FDA has now approved it for use in Six to 11-Year-Old Children with Severe Eosinophilic Asthma https://t.co/orAaFCkR92
Dr. John Cush RheumNow ( View Tweet)
